When a copy is not a copy: biosimilars v. generics

When a copy is not a copy: biosimilars v. generics

Peter Rankin, Andrew Tepperman
Life Sciences | Pharmaceuticals

Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.

Download PDF